» Articles » PMID: 22507683

Administration of Autologous Bone Marrow-derived Mononuclear Cells in Children with Incurable Neurological Disorders and Injury is Safe and Improves Their Quality of Life

Overview
Journal Cell Transplant
Date 2012 Apr 18
PMID 22507683
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Neurological disorders such as muscular dystrophy, cerebral palsy, and injury to the brain and spine currently have no known definitive treatments or cures. A study was carried out on 71 children suffering from such incurable neurological disorders and injury. They were intrathecally and intramuscularly administered autologous bone marrow-derived mononuclear cells. Assessment after transplantation showed neurological improvements in muscle power and a shift on assessment scales such as FIM and Brooke and Vignos scale. Further, imaging and electrophysiological studies also showed significant changes in selective cases. On an average follow-up of 15 ± 1 months, overall 97% muscular dystrophy cases showed subjective and functional improvement, with 2 of them also showing changes on MRI and 3 on EMG. One hundred percent of the spinal cord injury cases showed improvement with respect to muscle strength, urine control, spasticity, etc. Eighty-five percent of cases of cerebral palsy cases showed improvements, out of which 75% reported improvement in muscle tone and 50% in speech among other symptoms. Eighty-eight percent of cases of other incurable neurological disorders such as autism, Retts Syndrome, giant axonal neuropathy, etc., also showed improvement. No significant adverse events were noted. The results show that this treatment is safe, efficacious, and also improves the quality of life of children with incurable neurological disorders and injury.

Citing Articles

Safety and Efficacy of Autologous Bone Marrow Derived Mononuclear Cell Transplant in the Management of Various Neurological Disorders.

Kala S, Aggarwal A, Singh Rajput B, Kala C, Barman S Cureus. 2025; 16(12):e75617.

PMID: 39803099 PMC: 11725325. DOI: 10.7759/cureus.75617.


Stem cell therapy approaches for non-malignant diseases & non-haematological diseases in India: A systematic review.

Chavan C, Ray S, Kumar C Indian J Med Res. 2024; 160(5):411-427.

PMID: 39737504 PMC: 11683502. DOI: 10.25259/ijmr_2141_23.


A systematic review of cell therapy modalities and outcomes in cerebral palsy.

Akat A, Karaoz E Mol Cell Biochem. 2024; 480(2):891-922.

PMID: 39033213 DOI: 10.1007/s11010-024-05072-3.


Adverse events of cell therapy clinical trials in human chronic spinal cord injury, a systematic review and meta-analysis.

Davoudi-Monfared E, Abolghasemi R, Allahyari F, Farzanegan G Regen Ther. 2024; 27:381-397.

PMID: 38694447 PMC: 11061649. DOI: 10.1016/j.reth.2024.03.012.


Cell Therapy Strategies on Duchenne Muscular Dystrophy: A Systematic Review of Clinical Applications.

Akat A, Karaoz E Stem Cell Rev Rep. 2023; 20(1):138-158.

PMID: 37955832 DOI: 10.1007/s12015-023-10653-8.